ASCO 2022: A New Era in the Treatment of Metastatic Breast Cancer

Avan J. Armaghani, MD


June 22, 2022

Avan J. Armaghani, MD, provides a postconference perspective on data shared at ASCO 2022. The cumulative effect of the latest results from the DESTINY-Breast04 study are, in Dr Armaghani's view, "practice-changing," and perhaps most importantly by the consolidation of a new clinical category, HER2-low, which represents a more nuanced picture in the treatment of metastatic breast cancer. In the revised scheme, a subgroup of patients previously considered as HER2-negative are now redefined as an autonomous population, with an accompanying distinction in therapeutic approach.

This new formulation, together with parallel benefits Dr Armaghani describes in the triple-negative setting, amount to "a new era in how we treat breast cancer."


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.